Kornimate/medical-research-clean huggingface dataset:
clinical comparison of universal adhesives in terms of different application modes on the restoration of nccls

Conditions: Tooth Wear

Summary: the aim of this randomized, controlled, prospective clinical trial is to evaluate the performances of two different universal adhesives and an etch\&rinse adhesive in restoration of non-caries cervical lesions. twenty patients will receive restorations. lesions will be divided into 7 groups according to adhesive systems and application modes: gse: gluma universal- self etch, gsl: gluma universal-selective etching, ger: gluma universal-etch\&rinse, ase: all bond universal- self etch, asl: all bond universal- selective etching, aer: all bond universal- etch\&rinse, sb (control): single bond2+etch\&rinse. restorations (nano-hybrid composite) will be scored with regard to retention, marginal discoloration, marginal adaptation, recurrent caries and post operative sensitivity using modified usphs criteria after 48 months. two examiners who is not involved in the placement of restorations will conduct the evaluations. descriptive statistics will be performed using chi-square tests.


Eligibility criteria:
inclusion criteria: inclusion criteria will be as follows: 1. being 18 years or older, 2. having no medical or behavioral problems preventing then from attending review visits, 3. having at least 7 tooth with nccls (d) having antagonist teeth. exclusion criteria: exlusion criteria will be: 1. poor gingival health, 2. uncontrolled, rampant caries, 3. bruxism, 4. removable partial dentures, 5. xerostomia.
echocardiography, adherence to mediterranean diet (amds) and physical exercise in fatty liver

Conditions: Fatty Liver

Summary: nafld is associated with unhealthy lifestyle and obesity, without alcohol habits. an association of nafld with coronary artery disease and with impaired heart function was reported, but without considering severity of nafld and with the bias of including diabetes. aim: to challenge if severity of liver steatosis assessed by ultrasound bright liver score (bls) can predict the impairment of systolic heart function, assessed by echocardiography (ejection fraction, ef), diastolic function (assessed by e/a ratio), left ventricular mass, left atrial diameter.

method and measures: age, obesity (bmi) , dietary profile (assessed as adherence to mediterranean diet score, amds), physical activity profile, assessed by the baecke's physical exercise questionnaire, insulin resistance (assessed by homa) were all taken into account for their confounding and synergic effect. multiple regression analysis and odds ratio will be the statistical tools that will be used.receiver operator curve (roc) analysis will be applied in order to find the cut-off, if any, of the considered measures vs. nafld and significant abnormalities of echocardiography measures.

Eligibility criteria:
inclusion criteria: clinical diagnosis on fatty liver exclusion criteria: * diabetes * cancer * virus hepatitis * alcohol habits above 20 g/day (140 g/week) and any binge drinking * myocardial infarction, * valvular or congenital heart disease * heart failure * respiratory or renal insufficiency * rheumatic or autoimmune disease.

Keywords: diet
evaluation of neuroprotective effect of minocycline

Conditions: Retinal Detachment

Summary: this process appears as a incredible and progressive event that will not stop till reattachment of rpe and neurosensory retina happened . process of degeneration begins from first hours of rd (retinal detachment) establishment neuroprotection of photoreceptor following rd is a novel and debatable discussion encountered in recent years . how to stop this phenomena and neuroprotective agent role in this issue are a new interest of researcher. in the study the investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study


Eligibility criteria:
inclusion criteria: * age over 8 years old * gender of both sex * normal liver and renal function * informed consent received from all patients * no pregnancy and no lactation * minimal sun exposure exclusion criteria: * old rd * diabetic retina * previous retinal surgery crf\& liver disfunction rd + pvr \> b hyper sensitivity to tetracycline history previous mpc or prp patients unsuccessful sb (retina is off )
structural imaging and cognitive functions in adult stem cell transplant recipients treated with chemotherapy alone or in combination with radiotherapy

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Acute Undifferentiated Leukemia; Biphenotypic Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma

Summary: the purpose of this study is to learn about possible changes in brain anatomy and in thinking abilities, such as memory skills, in patients with cancer who receive treatment with chemotherapy alone or in combination with total body radiation before undergoing stem cell transplantation.


Eligibility criteria:
inclusion criteria: * diagnosed with acute myeloid leukemia (aml), acute lymphoblastic leukemia (all), acute undifferentiated or biphenotypic leukemia, myelodysplastic syndrome (mds), hodgkin's lymphoma, (hl) or non-hodgkin's lymphoma (nhl), and in complete remission at the time of enrollment * are scheduled to undergo conditioning treatment with (1) total body radiation (tbi) and chemotherapy or (2) chemotherapy alone prior to receiving a myeloablative allogeneic hsct * between 18 and 70 years of age. * are english speaking. * have capacity to give consent. healthy control inclusion criteria: * have no diagnosis of cancer except basal cell carcinoma * between 18 and 70 years of age. * are english speaking. * have capacity to give consent exclusion criteria: * patients with signs and/or symptoms of central nervous system disease as determined by their physician or by a brain mri, either at the time of enrollment or during the study period. * with disease progression at the time of enrollment or during the study period * with self-reported axis i psychiatric disorder (dsm-iv), major affective disorder (untreated), bipolar disorder, schizophrenia * with a history of a neurological disorder, neurodegenerative disease, or traumatic brain injury with loss of consciousness * with standard contraindications to mri examinations healthy control exclusion criteria: * exposure to chemotherapy or radiation therapy for any medical condition * with self-reported axis i psychiatric disorder (dsm-iv), major affective disorder (untreated), bipolar disorder, schizophrenia * with a history of neurological disorders, neurodegenerative disease, or traumatic brain injury with loss of consciousness * with standard contraindications to mri examinations

Keywords: mri
diabetic foot education

Conditions: Diabetes Mellitus; Diabetic Foot Disease

Summary: to determine the effect of foot care training given according to interpersonal relationship theory on foot care behaviour and diabetic foot self-efficacy.


Eligibility criteria:
inclusion criteria: * over 18 years of age, * diagnosis of type 2 dm for at least 6 months, * not having received planned diabetic foot training before, * volunteering to participate in the study, exclusion criteria: * neuropsychiatric drug use and disease that may affect education (dementia- alzheimer's and mental retardation etc.) * being visually impaired, * hearing impairment, * inability to speak turkish, * presence of active diabetic foot ulcer.

Keywords: diabetic foot diabetes mellitus patient education
the hope app study

Conditions: Type 2 Diabetes

Summary: this research study will test how a computer program (called the hope app) teaches diabetes care skills for older adults with diabetes. the study will compare those who receive diabetes education (10 educational modules and monthly health coaching) through the research program with those who receive care as usual.

the hope app offers a simple, high-impact, engaging, and immersive telehealth experience with the potential to become a ubiquitous diabetes management tool to transform diabetes patients into high performing drivers of their own care. the research team aims to scale the platform, develop features that are important to aging adults, and run a clinical trial to validate the hope app's health benefits. * specific aim 1: develop the hope app's state-of-the-art immersive patient engagement experience with automated onboarding, social networking and gamified dsme/s features to support long-term patient retention. in doing so, usability testing will be performed to ensure patient-facing features on the platform and patient-facing content and curriculum materials are functioning and well received by participants. * specific aim 2: develop the hope app's predictive analytic capabilities for population health management. * specific aim 3: conduct a clinical validation trial of the hope app intervention on six-month clinical outcomes (hemoglobin a1c), patient reported outcomes (diabetes distress) and engagement outcomes (patient retention, adherence to self-care behaviors). the research team intends to deliver a scalable hope app platform with a usable patient engagement portal designed for older adults and achieve decreases in blood glucose levels (hba1c) and depressive burden, and sustained patient engagement.

Eligibility criteria:
inclusion criteria: * aged 65 years and above * diagnosis of type 2 diabetes * english-speaking * baseline blood sugar value (hba1c) of 7.5% * internet access exclusion criteria: * aged less than 65 years * non english-speaking * unable to provide informed consent * diagnosis of type 1 diabetes * unable to use a computer or mobile device * medical condition for which participation is contraindicated (dialysis, pregnancy, use of insulin pump)

Keywords: older adults telehealth
incidence of paraneoplastic neurological syndromes and autoimmune encephalitis

Conditions: Paraneoplastic Neurological Syndrome; Autoimmune Encephalitis

Summary: this study aims to provide an estimate of the incidence of paraneoplastic neurological syndromes and autoimmune encephalitides in france between the years 2016 and 2018. the study will describe the incidence of antibody subtypes and regional variations.


Eligibility criteria:
inclusion criteria: - clinical diagnosis of paraneoplastic neurological syndrome (pns) or autoimmune encephalitis (ae) made by the referring physician to the national center for pns and ae in lyon between 2016 and 2018 exclusion criteria: * data on location of diagnosis missing * patients diagnosed out of the mainland french territory * patients for whom insufficient data was available
multifocal lens design evaluation

Conditions: Refractive Error; Presbyopia

Summary: the purpose of this study was to compare binocular high contrast, high illumination (hc/hi) visual acuity at near (40 centimeters) of new multifocal contact lenses against air optix® aqua multifocal contact lenses when worn for 9 hours.

each participant was randomized to a specific sequence of lens wear, during which each lens type was worn bilaterally for 9 hours to compare performance characteristics.

Eligibility criteria:
inclusion criteria: * sign written informed consent document. * have spectacles that provide acceptable vision and be willing to wear them if unable to wear the study lenses. * be presbyopic with a spectacle add ≥ 0.50 diopter. * currently wearing soft contact lenses at least 5 days a week. * other protocol-specified inclusion criteria may apply exclusion criteria: * eye injury or surgery within 12 weeks of enrollment in this trial. * pre-existing ocular irritation that would preclude contact lens fitting. * currently enrolled in any clinical trial. * evidence of systemic or ocular abnormality, infection, or disease which is likely to affect successful wear of contact lenses (for at least 9 hours) or use of their accessory solutions as determined by the investigator. * any use of medications for which contact lens wear could be contraindicated as determined by the investigator. * binocular visual acuity worse than 20/25. * corrected by monovision. * other protocol-defined exclusion criteria may apply.

Keywords: contact lenses multifocal
pozikids: exercise and comprehensive care to improve the quality of life of children and adolescents with cancer

Conditions: Exercise; Childhood Cancer

Summary: objective: to assess the feasibility of a supervised, controlled and personalised physical exercise programme and its potential efficacy in improving functional capacity and quality of life in children and adolescents with cancer. design: hybrid quasi-experimental pilot trial, clinical and phase i implementation. methods: the learning collaborative approach based on the institute for healthcare improvement breakthrough series collaborative model will be followed through quarterly plan-do-study-act (p-d-s-a) cycles. participants: for feasibility, at least, 45 patients will be included in 3 successive pdsa cycles of at least 15 patients each, aged 4-18 years diagnosed with any type of cancer. variables: clinical and socio-demographic, body composition, physical condition and mobility, quality of life, physical activity and implementation. intervention: everyone will receive a physical exercise intervention combining strength and aerobic capacity work. initially it will be carried out in the hospital setting, and later in streaming supervised by a professional. the intervention will be modelled through a formative evaluation process with the collaboration of all the agents involved, experimenting in each cycle with an increasingly adapted version of the exercise programme. statistical analysis: recruitment rates will be calculated, characteristics associated with project participation and adherence to the exercise programme will be identified. outcome variables will be compared before and after the intervention, identifying those with the greatest validity, reliability and sensitivity to change, which will then be used in phase ii and iii trials.


Eligibility criteria:
inclusion criteria: * patients diagnosed with cancer and other neoplasms * age between 4 and 18 years at the time of inclusion in the study * patients diagnosed with cancer and other malignancies aged between 4 and 18 years who are experiencing relapse * paediatric patients requiring chemotherapy, radiotherapy, or oncological surgery * patients and parents or guardians who agree to participate in the study and sign the informed consent forms by current legislation depending on the patient's age. exclusion criteria: * patients with cognitive deficits that prevent participation in and performance of physical exercise interventions. * patients with severe neurological pathology with a motor impairment that prevents or significantly hinders the performance of physical exercise * patients and families or guardians with language comprehension difficulties that make it difficult or impossible to carry out the physical exercise intervention. * patients \< 16 years with a functional status score according to lanskyi scale \<60% * patients \> 16 years with karnofsky scale \<60%. * any other criteria that the physician deems inappropriate for participation in the study
individualizing corticosteroid use in pneumonia

Conditions: Pneumonia

Summary: in this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. this study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in the blood called c- reactive protein (crp). the overall goal is to reduce an individual's exposure to steroids and the risk of potential side effects thereby increasing the potential benefit of using steroids to control inflammation in pneumonia.


Eligibility criteria:
inclusion criteria: * hospitalized adult (≥ 18 years) patients. * community acquired pneumonia. exclusion criteria: * contraindications or unwillingness to use corticosteroids by patient or provider. * history of adrenal insufficiency, septic shock, or another absolute indication for steroid use. * suspected pulmonary vasculitis or other autoimmune pulmonary disorder. * positive pregnancy test * comfort care.
study of safety and efficacy of ang-3070 in chronic kidney disease

Conditions: Glomerular Disease; Proteinuria

Summary: the major objective is to demonstrate the safety and efficacy of ang-3070 in patients with primary glomerular disease and persistent proteinuria.

to evaluate the safety and efficacy of ang-3070 in patients with primary glomerular disease and persistent proteinuria while on the soc, as measured by a reduction in the 24-hour urinary protein excretion.

Eligibility criteria:
inclusion criteria: 1. male or female participants aged 18 and older. 2. diagnosis of a primary glomerular disease confirmed from a past renal biopsy. participants with genetic forms of fsgs may be enrolled without a renal biopsy if the clinical picture is consistent with the genetic testing results. 3. estimated glomerular filtration rate (egfr) by chronic kidney disease epidemiology collaboration (ckd-epi) ≥ 40 ml/min/1.73m2. 4. urinary protein excretion ≥ 1 g/day on a 24-hour urine collection. 5. all participants must be on the soc therapy, including the maximally tolerated/recommended doses of an acei or arb, but not both. exclusion criteria: 1. positive hepatitis b (hbv), hepatitis c (hcv), or human immunodeficiency virus (hiv) viral screening; historical or during screening. 2. aspartate aminotransferase (ast) or alanine aminotransferase (alt) or total bilirubin \> 2 x uln. 3. hemoglobin a1c \> 8.5%. 4. known predisposition to bleeding and/or thrombosis 5. type i diabetes mellitus. 6. renal disease secondary to systemic disease including but not limited to: systemic lupus erythematosus, anti-neutrophil cytoplasmic antibodies -associated diseases, anti-glomerular basement disease, secondary forms of focal segmental glomerulosclerosis, renal diseases associated with para-proteinemias, c3 glomerulopathy, and diabetic kidney disease.

Keywords: glomerular disease chronic kidney disease proteinuria
kmc implementation research for accelerating scale-up in oromia region, ethiopia

Conditions: Low Birth-weight

Summary: the main objective is to implement kangaroo mother care (kmc) at selected facilities in addis ababa and oromia regions to achieve high effective coverage in the catchment population.

to achieve the objective summarized above, the investigators will engage in an iterative process using program learning and quantitative data to continuously improve models in order to enhance uptake of kmc in two phases. in phase 1, the model will undergo an iterative process whereby every three months, the investigators will analyze the data collected and improve the model until it is reached at a model that achieves effective kmc coverage of at least 80%. in phase 2, we will scale the successful model to all selected facilities. the investigators' primary outcomes will be effective coverage of kmc at 7 days of age, and effective coverage of kmc at 7 days after discharge from the facility. effective coverage will be defined as adoption of skin to skin care for at 8 least hours and exclusive breastfeeding in the 24 hours prior to assessment

Eligibility criteria:
inclusion criteria: * all newborns who are less than 2000 gm born within the study facilities during the study period. exclusion criteria: * newborns who are sick per predefined criteria will not be provided kmc until they have been stabilized. criteria for delay of initiation include: critical illness including apnea, decreased respiratory rate \<20 breaths per minute, grunting, cyanosis, severe chest in-drawing, convulsions, unconsciousness, and severe hypothermia \<32°f.
anti-müllerian hormone and embryo aneuploidy

Conditions: Infertility; Aneuploidy

Summary: the goal of this observational study is to determine is there an association between the rates of aneuploidy and the different ranges of serum antimullerian hormone (amh) levels. retrospective, single-centre study of patients undergoing ivf and preimplantation genetic testing with aneuploidy at the blastocyst stage between january 2018 and december 2022.


Eligibility criteria:
inclusion criteria: * all started cycles planned to be followed by preimplantation genetic testing for aneuploidies (pgt-a). pgt-a is proposed to the couples for the following reasons: advanced maternal age, recurrent miscarriage, repeated implantation failure or severe male infertility factor; it is also offered to all patients with a good prognosis who desired information regarding the ploidy status of their embryos. exclusion criteria: * data from oocyte donation cycles

Keywords: amh ivf aneuploidy pgt-a anti-mullerian hormone oocyte quality
efficacy and safety study of hzt-501 in subjects requiring nonsteroidal anti-inflammatory drug (nsaid) treatment

Conditions: Ulcer

Summary: the purpose of this study is to evaluate whether hzt-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.

hzt-501 is a combination product including ibuprofen and the acid reducing agent famotidine. the study is designed to determine whether the combination product reduces the rate of ulcer development in subjects who require long-term daily use of ibuprofen. subjects will be assigned randomly, in approximately a 2:1 ratio, to treatment with either hzt-501 (ibuprofen 800 mg/famotidine 26.6 mg) or ibuprofen (800 mg) three times daily for a 24 week treatment period or until they develop either an endoscopically-diagnosed upper gastrointestinal ulcer and/or prohibitive toxicity. subjects will visit the study center for screening and at weeks 4, 8, 16, and 24. physical exams will be performed, and clinical laboratory measurements made, at selected times during the study. endoscopic exams will be performed during screening and at weeks 8, 16, and 24. subjects will be contacted four weeks following study completion. study with completed results acquired from horizon in 2024.

Eligibility criteria:
inclusion criteria: * expected to require daily administration of an nsaid for at least the coming six months for conditions such as osteoarthritis, rheumatoid arthritis, chronic low back pain, chronic regional pain syndrome, and chronic soft tissue pain. * did not use a nsaid within the 30 days prior to study entry exclusion criteria: * history of erosive esophagitis * history of any of the following serious gastrointestinal complications: * perforation of ulcers, * gastric outlet obstruction due to ulcers, or * gastrointestinal bleeding. * active cardiac, renal, and/or hepatic disease * current helicobacter pylori (h. pylori) infection * use of an acid suppressant agent, misoprostol, or more than 325 mg/day of aspirin within the 14 days prior to study entry. * uncontrolled diabetes * uncontrolled hypertension * positive pregnancy test at screening * positive test at screening for human immunodeficiency virus (hiv), hepatitis b, or hepatitis c. * currently participating, or participation within 30 days prior to study entry, in an investigational drug study please note that there are other additional criteria. the study center will determine if patients meet all of the criteria.

Keywords: ibuprofen famotidine ulcers nsaids pain arthritis chronic regional pain syndrome chronic soft tissue pain osteoarthritis rheumatoid arthritis chronic low back pain